CTOs on the Move

Beam Therapeutics

www.beamtx.com

 
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.beamtx.com
  • 26 Landsdowne Street 2nd Floor
    Cambridge, MA USA 02139
  • Phone: 857.327.8775

Executives

Name Title Contact Details
Nicholas Meghri
 Associate Director, IT Business Partnership Profile
Brian Riley
 Senior Vice President of Technical Operations Profile
Brad Dutot
 Vice President, Information Technology Profile

Funding

Beam Therapeutics raised $13M on 04/27/2018
Beam Therapeutics raised $74M on 05/14/2018
Beam Therapeutics raised $11M on 03/06/2019
Beam Therapeutics raised $260M on 01/19/2021

Similar Companies

Transcend Orthotics & Prosthetics

Transcend orthotists and prosthetists are fully certified and experienced in serving the needs of our patients.

Tricol Biomedical

Tricol Biomedical is dedicated to significantly advancing the standard of care in hemostatic and wound care management with a broad array of products.

Nucryst Pharmaceuticals

Nucryst Pharmaceuticals Corp. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Medicines Company

The Medicines Company`s purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.

Neurelis

Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company devoted to developing treatment options for epilepsy, while also investigating new treatment options for the unmet needs of central nervous system (CNS) disorders.